Nippon Chemiphar Successfully Reverses Decline

Annual Results See Company Make Up Shortfall From Earlier In The Year

Japan’s Nippon Chemiphar gets a grip on a decline in pharmaceutical sales seen earlier this year, on the back of strong sales of generic drugs launched last year. The company also expects an upward impact from expanded sales of generic drugs achieved through sales channel diversification efforts for its current financial year ending 31 March 2022. 

Yen
Nippon Chemiphar expects an upswing in generics sales for its current financial year ending 31 March 2022 • Source: Alamy

Nippon Chemiphar Co Ltd has managed to “nearly level year-on-year sales” as the company reported that it had managed to limit the decline in its pharmaceuticals sales to just 0.7% for the financial year ending 31 March 2021.

The full-year stable sales figure comes after the Japanese company reported a 7.5% rate of year-on-year decline in its pharmaceuticals...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business